Objetivo: descrever as ações realizadas pelos membros da Liga Acadêmica de Enfermagem em Estomaterapia de uma universidade pública do sul do Brasil na prevenção de Incontinência Urinária no contexto ...da pandemia da Covid-19. Método: trata-se de um relato de experiência sobre as divulgações científicas da temática de incontinência urinária que ocorreram no período de outubro de 2020 a março de 2021 por meio de plataformas digitais. Para tanto, foi realizado inicialmente a capacitação teórica, de forma remota, sobre incontinência urinária feminina e posteriormente elaborou-se e disseminou-se os informativos digitais. Resultados: Após a capacitação teórica, um folder informativo foi elaborado com ações preventivas e os principais cuidados com a incontinência urinária. Utilizou-se a rede social Instagram para veicular os informes sobre a temática. Ao total, foram compartilhadas seis informações baseadas em evidências científicas que foram elaborados pelos próprios membros da liga. A participação dos usuários foi identificada por meio de comentários. Em adição, foi estruturado um capítulo de livro voltado aos profissionais enfermeiros e acadêmicos de enfermagem na assistência aos pacientes incontinentes. Conclusão: O Instagram viabilizou, no período da pandemia, o compartilhamento de informações para a prevenção de incontinência urinária no público feminino da comunidade acadêmica e externa a ela. O capítulo do livro motivou os membros da liga a se aproximar da temática e disseminar o conhecimento acadêmico de qualidade.
Steve Bates, who heads the BioIndustry Association, a biotech sector lobby group, cited many examples of transformative drugs that had been successfully introduced into the NHS, from statins that ...combated cardiovascular disease to treatments for cystic fibrosis and rare diseases. Gilead has worked with scientists at Accelerated Clinical Trials Ltd to develop a blood cancer treatment. The NHS said it directly commissioned a range of services and treatments nationally “including by using our strength as a single-payer health system to negotiate commercial deals for cutting-edge NICE-approved treatments”.
On one occasion, she was the doctor in charge when a group of 30 was brought in to her hospital, all poisoned with carbon monoxide on a canal boat. The story of her leadership of the Medicines and ...Healthcare products Regulatory Agency is of two huge imperatives — first, to chart a new path for the agency after Brexit forced it to leave the embrace of the European Medicines Agency, then to set the international pace in approving life-saving Covid vaccines and therapeutics. Last month, that ambition bore fruit in a government announcement that the MHRA would operate a more streamlined approval process for the most cutting-edge medicines and devices in the hope of attracting global pharmaceutical companies to develop their medicines in the UK.
...the sixth-largest pharma company by global sales in 2022 has dropped the idea of a pivotal trial involving 40,000 UK patients, “after a careful evaluation of several factors that drive investment ...decisions in research and development activities and plans for inclisiran in the UK”. While the health service remained focused on the importance of preventing heart disease, the drive would in future probably centre on long-established statins, the person suggested. John Bell, regius professor of medicine at Oxford university, said the setbacks with the inclisiran programme were “bad for patients, bad for Novartis, and bad for the health system”, but that the NHS could learn lessons.
The government is aiming to secure homegrown supplies of the mRNA technology that has proved a crucial weapon in the fight against Covid-19 and offers the prospect of transforming treatment for other ...conditions such as cancer. Javid had sought and secured “a personal mandate” from Boris Johnson, UK prime minister, to negotiate the deal, he added. Johnson said the investment with Moderna would “guarantee jabs in the arms” and create jobs, as the Boston-based biotech develops vaccines for other respiratory diseases including flu and respiratory syncytial virus.
PDF
